Neuroprotection and stroke: time for a compromise
- 1 November 2007
- journal article
- review article
- Published by Wiley in Journal of Neurochemistry
- Vol. 103 (4), 1302-1309
- https://doi.org/10.1111/j.1471-4159.2007.04866.x
Abstract
In April 2007, there existed a repertory of 286 trials concerned with acute ischemic stroke on the Stroke Trials Registry (http://www.strokecenter.org/trials/), of which 209 trials were considered as complete (with no evidence of patient benefit unless one considers the much hard fought for and modest results of the tPA studies). Among other questions arising from such failures, one can wonder whether the plethora of pharmacological agents that exhibited neuroprotective properties in pre-clinical studies were selected for clinical trials entirely based upon their experimental efficacy. This mini-review will try to point out some of the weaknesses that could underline the failure of both researchers and clinicians involved in the field of stroke to obtain their ultimate goal--brain protection.Keywords
This publication has 64 references indexed in Scilit:
- Translating animal research into clinical benefitBMJ, 2007
- Comparison of treatment effects between animal experiments and clinical trials: systematic reviewBMJ, 2006
- Magnetic resonance perfusion diffusion mismatch and thrombolysis in acute ischaemic stroke: a systematic review of the evidence to dateJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS)Stroke, 2006
- Ischemic Thresholds for Gray and White MatterStroke, 2006
- Toward a Multimodal Neuroprotective Treatment of StrokeStroke, 2006
- 1,026 Experimental treatments in acute strokeAnnals of Neurology, 2006
- The complexity of tissue-type plasminogen activator: can serine protease inhibitors help in stroke management?Emerging Therapeutic Targets, 2004
- Metalloproteinase Inhibition Reduces Thrombolytic (Tissue Plasminogen Activator)–Induced Hemorrhage After Thromboembolic StrokeStroke, 2000
- Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug DevelopmentStroke, 1999